Eli Lilly: Biggest Company in America Within 5 Years?

The short answer: Jordi Visser believes Eli Lilly will become the biggest company in America within five years, bigger even than Nvidia. He says Lilly is his largest long position. His case: healthcare is non-cyclical, hard for AI to disrupt quickly, funded by governments and insurers, and positioned to benefit from AI-driven drug discovery. It's one investor's opinion, not a forecast or advice.

From The Pomp Podcast, hosted by Anthony Pompliano, with guest Jordi Visser, veteran macro investor and author of the VisserLabs Substack. Episode released October 24, 2026.

Could Eli Lilly be the biggest company in America? Jordi Visser thinks so, and he put a timeline on it. On the October 24 episode of The Pomp Podcast, the veteran macro investor and VisserLabs author told host Anthony Pompliano that he expects Lilly to become the largest U.S. company within five years. He said he expects it to be bigger than Nvidia, and he said Lilly is currently his biggest long position, ahead of Nvidia. He made the call in a week he described as brutal for AI stocks, while Lilly was hitting new highs.

Visser's thesis has four parts.

1. Healthcare is hard to disrupt in the next five years. While AI threatens to upend industries from software to services, Visser argues healthcare is different. Drug approvals move through a slow, regulated process, so incumbents with approved products and pipelines aren't easily displaced in the near term.

2. It's non-cyclical, and someone else is paying. Visser contrasted healthcare with energy. He argued healthcare takes a far larger share of U.S. consumer spending, and that it's largely paid for by governments and insurers, which makes demand less sensitive to the economic cycle. For context on how big healthcare spending is, see the CMS national health expenditure data.

3. AI is a tailwind, not a threat. Visser sees AI accelerating drug discovery, which benefits companies with the biggest research datasets.

4. The alternatives are cyclical. He described AI hardware names like Nvidia and Micron as more cyclical, exposed to GPU and power constraints. In his view, Lilly offers growth without that cyclicality.

Visser highlighted a Lilly AI initiative where many companies share data on a Lilly-built platform. He called it a "Manhattan-style project." That appears to refer to Lilly TuneLab, which Lilly launched in September 2025. According to Lilly, TuneLab gives biotech companies access to AI drug-discovery models trained on Lilly research data that cost over $1 billion to obtain. Partners contribute their own data in return, and the platform uses federated learning so each company's data stays private.

Visser cited a specific number of participating companies on the show. We haven't independently verified that figure, so we've left it out here.

This was the most interesting part of the conversation for investors. Much of the market's anxiety right now is about which industries AI will disrupt. Visser flips the question: which large industries are the least likely to be disrupted soon, and which actually get better with AI?

Healthcare fits both, in his view. Regulation slows disruption, while AI speeds up research. Visser also said the broader S&P 1500 life sciences, biotech and pharma group was at a 52-week high as AI stocks sold off, a sign, he argued, that investors are already rotating toward that idea.

Visser pointed to Lilly's long run of strong returns. He said the stock has been up 10 years in a row with a compound annual growth rate above 30%. Those are his figures from the episode, and we'd encourage readers to check them against market data.

A major driver of Lilly's recent growth has been its tirzepatide medicines for diabetes and weight management. That includes Zepbound, which the FDA approved for chronic weight management in 2023.

Visser made a bold call, and bold calls deserve a risk check:

Visser's view is that the structural tailwinds outweigh these. Investors should weigh them for themselves.

Don't read this as Visser turning bearish on AI. On the same episode, he said AI is not a bubble but inevitable. His Lilly call is about where AI's benefits land. In his framing, healthcare is one of the biggest winners of AI, while being protected from the disruption hitting other sectors. For more from this conversation, see Is quantum computing a threat to bitcoin? and Muse AI agent memory: why Jordi Visser relies on it.

Jordi Visser believes it will within five years. That's his opinion on The Pomp Podcast, not a forecast or investment advice.

He cites healthcare's non-cyclical demand, slow regulatory disruption, government and insurer funding, and AI-driven drug discovery.

An AI and machine learning platform Lilly launched in September 2025 that gives biotech companies access to drug-discovery models trained on Lilly's research data.

He said on the October 24, 2026 episode that Eli Lilly is his biggest long, followed by Nvidia.

Anthony Pompliano is an entrepreneur, investor, and author who serves as Chairman and CEO of Silvia, Inc (SVIA) and invests through Pomp Investments. He is the host of The Pomp Podcast, where he interviews founders, investors and economists about bitcoin, markets, AI and the economy. This article is based on his October 24, 2026 conversation with Jordi Visser, with outside facts checked against the sources listed above. Follow Pomp on X (https://x.com/APompliano).

Get notified for every new Pomp Podcast episode.

Subscribe for free to learn alongside Anthony Pompliano.

This article reflects the opinions of the guest and host as shared on The Pomp Podcast. It is guest opinion, not investment advice. Do your own research before making any investment decision.